Hengenix

Hengenix Biotech, Inc. focuses on developing and providing high-quality, innovative, and affordable drugs for patients worldwide to treat a range of chronic and life-threatening diseases, with an emphasis on oncology and autoimmune disorders. Hengenix is a subsidiary of Shanghai Henlius Biotech, Inc., a global biopharmaceutical company established in 2010. Henlius has a diversified pipeline of over 20 innovative monoclonal antibodies (mAbs), including Hanlikang® (HLX01, Rituximab Injection, the first biosimilar commercially launched in China), Hanquyou® (HLX02, Trastuzumab Injection, known as Zercepac® in the EU, the first Chinese mAb biosimilar approved in both the EU and China), two products under NDA review, and over 20 clinical studies across 10 products and eight combination therapies globally.